Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1806310
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
Taysha Gene Therapies filed a routine 8-K, no major news.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on June 18, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Taysha Gene Therapies is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material events or financial information that would inherently increase risk.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Dallas, Texas (location) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is for reporting purposes, specifically covering Regulation FD Disclosures and Financial Statements and Exhibits, as of June 18, 2024.
What is the exact date of the earliest event reported?
The earliest event reported is dated June 18, 2024.
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
The principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Does this filing announce any new material events or financial results?
Based on the provided text, this filing appears to be a standard current report and does not explicitly announce new material events or specific financial results beyond the reporting requirement itself.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-18 07:45:05
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d851091d8k.htm (8-K) — 27KB
- d851091dex991.htm (EX-99.1) — 45KB
- d851091dex992.htm (EX-99.2) — 42KB
- g851091ex99_2s10g1.jpg (GRAPHIC) — 141KB
- g851091ex99_2s11g1.jpg (GRAPHIC) — 164KB
- g851091ex99_2s12g1.jpg (GRAPHIC) — 90KB
- g851091ex99_2s13g1.jpg (GRAPHIC) — 118KB
- g851091ex99_2s14g1.jpg (GRAPHIC) — 139KB
- g851091ex99_2s15g1.jpg (GRAPHIC) — 157KB
- g851091ex99_2s16g1.jpg (GRAPHIC) — 134KB
- g851091ex99_2s17g1.jpg (GRAPHIC) — 146KB
- g851091ex99_2s18g1.jpg (GRAPHIC) — 130KB
- g851091ex99_2s19g1.jpg (GRAPHIC) — 149KB
- g851091ex99_2s1g1.jpg (GRAPHIC) — 56KB
- g851091ex99_2s20g1.jpg (GRAPHIC) — 149KB
- g851091ex99_2s21g1.jpg (GRAPHIC) — 53KB
- g851091ex99_2s22g1.jpg (GRAPHIC) — 23KB
- g851091ex99_2s23g1.jpg (GRAPHIC) — 30KB
- g851091ex99_2s24g1.jpg (GRAPHIC) — 23KB
- g851091ex99_2s25g1.jpg (GRAPHIC) — 151KB
- g851091ex99_2s2g1.jpg (GRAPHIC) — 222KB
- g851091ex99_2s3g1.jpg (GRAPHIC) — 109KB
- g851091ex99_2s4g1.jpg (GRAPHIC) — 113KB
- g851091ex99_2s5g1.jpg (GRAPHIC) — 143KB
- g851091ex99_2s6g1.jpg (GRAPHIC) — 100KB
- g851091ex99_2s7g1.jpg (GRAPHIC) — 123KB
- g851091ex99_2s8g1.jpg (GRAPHIC) — 151KB
- g851091ex99_2s9g1.jpg (GRAPHIC) — 159KB
- 0001193125-24-163050.txt ( ) — 4360KB
- tsha-20240618.xsd (EX-101.SCH) — 3KB
- tsha-20240618_lab.xml (EX-101.LAB) — 18KB
- tsha-20240618_pre.xml (EX-101.PRE) — 11KB
- d851091d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 18, 2024. 99.2 Corporate presentation, dated June 18, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: June 18, 2024 Kamran Alam Chief Financial Officer